Sources Sought Notice -Analysis of Anti-Cancer Chemicals and Pharmaceutical Formulations
General Information
-
Document Type: Sources Sought Notice Solicitation Number: Reference-Number-SS-NCI-TSB-2007-1 Posted Date: Oct 27, 2006 Original Response Date: Nov 13, 2006 Current Response Date: Nov 13, 2006 Original Archive Date: Nov 28, 2006 Current Archive Date: Nov 28, 2006 Classification Code: B — Special studies and analysis – not R&D Naics Code: 541710 — Research and Development in the Physical, Engineering, and Life Sciences
Contracting Office Address
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702, UNITED STATES
Description
This Source Sought Notice (SS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this SS is to identify qualified small businesses including 8(a), HUBZone, or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted. As a result of this SS, the NCI may issue a Request for Proposal (RFP). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this SS or the NCI?s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. It is anticipated that three (3) cost-reimbursement, completion type contracts would be awarded for a period of five (5) years with an option for yearly extensions up to two (2) additional years.
The National Cancer Institute is seeking qualified small businesses including 8(a), HUBZone, or Service Disabled Veteran-owned business concerns to provide support to NCI’s Pharmaceutical Resources Branch (PRB), Development Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD) in providing analysis of bulk drug substances and formulated drug products. Please click on the following link for more information: http://www.fbo.gov/spg/HHS/NIH/FCRF/Reference%2DNumber%2DSS%2DNCI%2DTSB%2D2007%2D1/SynopsisR.html
